Does the combined introduction of routine treatments (beta-blockers, nitroglycerin, aspirin, and thrombolytics) reduce in-hospital mortality in patients with acute myocardial infarction?
The combined introduction of routine treatments including beta-blockers, nitroglycerin, aspirin, and thrombolytics was associated with an almost 40% reduction in in-hospital mortality for acute myocardial infarction.
Beta-blockers, nitrates, aspirin and thrombolytic drugs have each separately been shown to reduce mortality in acute myocardial infarction, but the effect of these treatments combined during routine coronary care has not been assessed. The coronary care unit at Ostra Hospital services a stable community of 250,000 inhabitants. Since 1984 all patients have been entered into a computerized database. In addition, information on age, sex, discharge diagnosis and hospital outcome is also available for patients admitted between 1979 and 1983. In 1984, routine treatment with intravenous beta-blockers was introduced, to be followed in 1986 by intravenous nitroglycerin and in 1988 by aspirin in all patients without contraindications. Since 1988, intravenous thrombolytic treatment has been also given routinely to all patients with ST-elevation and chest pain < 6 h. Despite a similar number of patients and an increasing median age, the in-hospital mortality has declined from 18.5% in 1979 to 11.8% in 1990 (P < 0.01). It is concluded that mortality from acute myocardial infarction has declined by almost 40% since 1979. This reduction cannot be explained by a single major therapeutic intervention but may be attributed to the combined use of multi-lead monitoring, early use of beta-blockers, nitroglycerin, aspirin and thrombolytic agents.
Dellborg et al. (1994) studied this question.